GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » ROC (Joel Greenblatt) %

Axonics (Axonics) ROC (Joel Greenblatt) % : -52.32% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Axonics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Axonics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -52.32%.

The historical rank and industry rank for Axonics's ROC (Joel Greenblatt) % or its related term are showing as below:

AXNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1491.09   Med: -368.54   Max: -3.1
Current: -3.1

During the past 8 years, Axonics's highest ROC (Joel Greenblatt) % was -3.10%. The lowest was -1491.09%. And the median was -368.54%.

AXNX's ROC (Joel Greenblatt) % is ranked worse than
51.65% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: -0.61 vs AXNX: -3.10

Axonics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 58.90% per year.


Axonics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Axonics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics ROC (Joel Greenblatt) % Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -618.45 -118.63 -94.77 -90.16 -5.74

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -95.10 20.55 14.09 16.96 -52.32

Competitive Comparison of Axonics's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Axonics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Axonics's ROC (Joel Greenblatt) % falls into.



Axonics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.243 + 79.94 + 9.2790000000001) - (28.979 + 0 + 15.06)
=102.423

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(50.529 + 93.187 + 5.508) - (30.522 + 0 + 16.409)
=102.293

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Axonics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-60.824/( ( (10.76 + max(102.423, 0)) + (17.037 + max(102.293, 0)) )/ 2 )
=-60.824/( ( 113.183 + 119.33 )/ 2 )
=-60.824/116.2565
=-52.32 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axonics  (NAS:AXNX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Axonics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Axonics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920